Effect of Oral Magnesium Oxide Supplementation on Cisplatin-Induced Hypomagnesemia in Cancer Patients: A Randomized Controlled Trial

Maryam Zarif Yeganeh, Masoud Vakili, Ali Shahriari-Ahmadi, Marzieh Nojomi, Maryam Zarif Yeganeh, Masoud Vakili, Ali Shahriari-Ahmadi, Marzieh Nojomi

Abstract

Background: Hypomagnesaemia is one of the main side effects of cisplatin-based chemotherapy regimens in cancer patients. The aim of the current investigation was to evaluate the effect of oral magnesium oxide (MgO) supplementation on cisplatin-induced hypomagnesemia.

Methods: This parallel-randomized controlled, open label trial was conducted in a hospital of Iran University of Medical Sciences in Tehran between December 2009 and May 2011. Participants were 69 adult patients with newly diagnosed non- leukemia neoplasms candidate for starting cisplatin-based chemotherapy. Oral MgO supplement according to cisplatin dose (500 mg MgO per 50 mg/m(2) of cisplatin) as 2-3 divided daily doses was started after completion of each chemotherapy cycle and continued to the next cycle for the intervention group. Patients in the control group did not receive any supplementation. Serum magnesium (Mg) was measured before each chemotherapy cycle. The main outcome was measuring serum Mg change and hypomagnesaemia rate during chemotherapy treatment.

Results: Sixty-two participants (31 intervention- 31 controls) enrolled into the study. Serum Mg levels showed significant difference between the two groups (P=0.01). There was a significant decrease in serum Mg of the control group (P=0.001). At the end of follow-up period prevalence of hypomagnesaemia in the intervention group was 10.7% versus 23.1% in the control group.

Conclusion: Continuously oral supplementation with MgO according to cisplatin dose (500 mg MgO per 50 mg/m(2) cisplatin) as 2-3 divided daily doses at rest days between chemotherapy cycles reduces the decline in serum Mg levels and also the prevalence of hypomagnesaemia in cancer patients.

Keywords: Cancer; Cisplatin; Hypomagnesaemia; Magnesium; Magnesium oxide.

Figures

Fig. 1:
Fig. 1:
Trend of serum magnesium levels (mean) during cycles of cisplatin-based chemotherapy in cancer patients
Fig. 2:
Fig. 2:
Percentage of hypomagnesaemia during cycles of cisplatin-based chemotherapy in cancer patients

References

    1. Schilsky RL, Anderson T. (1979). Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med, 90 ( 6): 929–31.
    1. Hill J, Blachley J, Trotter M. (1978). Hypomagnesemia, hypocalcemia, and hypokalemia with cis-platinum treatment. Clin Res, 26 ( 2): 780A.
    1. RUD RK. (2014). Magnesium. In: Modern Nutrition in Health and Disease. Eds; Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR. 11th ed, Lippincott Williams & Wilkins Press; Philadelphia, pp. 159– 178.
    1. Kelepouris E, Agus ZS. (1998). Hypomagnesemia: renal magnesium handling. Semin Nephrol, 18( 1): 58–73.
    1. Quamme GA. (1997). Renal magnesium handling: new insights in understanding old problems. Kidney Int, 52 ( 5): 1180–95.
    1. Weiner MW, Jacobs C. (1983). Mechanism of cisplatin nephrotoxicity. Fed Proc, 42 ( 13): 2974–8.
    1. Vogelzang NJ, Torkelson JL, Kennedy BJ. (1985). Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer, 56 ( 12): 2765–70.
    1. Schilsky RL, Barlock A, Ozols RF. (1982). Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep, 66 ( 9): 1767–9.
    1. Mavichak V, Wong NL, Quamme GA, Magil AB, Sutton RA, Dirks JH. (1985). Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int, 28 ( 6): 914–21.
    1. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP. (1988). Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther, 44 ( 2): 164–72.
    1. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. (2010). Mechanisms of cisplatin nephrotoxicity. Toxins (Basel), 2 ( 11): 2490–518.
    1. Yao X, Panichpisal K, Kurtzman N, Nugent K. (2007). Cisplatin nephrotoxicity: a review. Am J Med Sci, 334 ( 2): 115–24.
    1. Hodgkinson E, Neville-Webbe HL, Coleman RE. (2006). Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol), 18 ( 9): 710– 8.
    1. Blachley JD, Hill JB. (1981). Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med, 95 ( 5): 628–32.
    1. Bell DR, Woods RL, Levi JA. (1985). cis-Diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting. Eur J Cancer Clin Oncol, 21( 3): 287–90.
    1. Buckley JE, Clark VL, Meyer TJ, Pearlman NW. (1984). Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med, 144 ( 12): 2347–8.
    1. Vokes EE, Mick R, Vogelzang NJ, Geiser R, Douglas F. (1990). A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia. Br J Cancer, 62 ( 6): 1015– 7.
    1. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. (1996). Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol, 14 ( 11): 2923–32.
    1. Stewart AF, Keating T, Schwartz PE. (1985). Magnesium homeostasis following chemotherapy with cisplatin: a prospective study. Am J Obstet Gynecol, 153 ( 6): 660–5.
    1. Ashraf M, Scotchel PL, Krall JM, Flink EB. (1983). Cis-Platinum-induced hypomagnesemia and peripheral neuropathy. Gynecol Oncol, 16 ( 3): 309–18.
    1. Crook MA. (1994). Hypophosphataemia and hypokalaemia in patients with hypomagnesaemia. Br J Biomed Sci, 51 ( 1): 24–7.
    1. Hayes FA, Green AA, Senzer N, Pratt CB. (1979). Tetany: a complication of cis-dichlorodiammineplatinum(II) therapy. Cancer Treat Rep, 63 ( 4): 547–8.
    1. Lajer H, Kristensen M, Hansen HH, Nielsen S, Frøkiaer J, Ostergaard LF, Christensen S, Daugaard G, Jonassen TE. (2005). Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol, 56 ( 5): 535– 42.
    1. Lam M, Adelstein DJ. (1986). Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis, 8 ( 3): 164–9.
    1. Lajer H, Daugaard G. (1999). Cisplatin and hypomagnesemia. Cancer Treat Rev, 25 ( 1): 47–58.
    1. Vallee BL, Wacker WE, Ulmer DD. (1960). The magnesium-deficiency tetany syndrome in man. N Engl J Med, 262 ( 28): 155–61.
    1. Assadi F. (2010). Hypomagnesemia: an evidence-based approach to clinical cases. Iran J Kidney Dis, 4 ( 1): 13–9.
    1. Macaulay VM, Begent RH, Phillips ME, Newlands ES. (1982). Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy. Cancer Chemother Pharmacol, 9 ( 3): 179–81.
    1. Martin M, Diaz-Rubio E, Casado A, Lopez Vega JM, Sastre J, Almenarez J. (1992). Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol, 15 ( 4): 348–51.
    1. Evans TR, Harper CL, Beveridge IG, Wastnage R, Mansi JL. (1995). A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer, 31A ( 2): 174– 8.
    1. Willox JC, McAllister EJ, Sangster G, Kaye SB. (1986). Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer, 54 ( 1): 19–23.
    1. Rosenthal CJ, Khulpateea N, Boyce J, Mehrotra S, Tamarin S. (1983). Effective chemotherapy for advanced carcinoma of the cervix with bleomycin, cisplatin, vincristine, and methotrexate. Cancer, 52 ( 11): 2025–30.
    1. Mavichak V, Coppin CM, Wong NL, Dirks JH, Walker V, Sutton RA. (1988). Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man. Clin Sci (Lond), 75 ( 2): 203–7.
    1. Netten PM, de Mulder PH, Theeuwes AG, Willems JL, Kohler BE, Wagener DT. (1990). Intravenous magnesium supplementation during cisdiammine-dichloroplatinum administration prevents hypomagnesemia. Ann Oncol, 1 ( 5): 369–72.
    1. Lofts FJ, Evans TR, Wastnage R, Mansi JL. (1996). Magnesium supplements with cisplatin chemotherapy. Eur J Cancer, 32A ( 3): 556– 7.
    1. Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcislo K, Szczylik C. (2008). Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer (Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't), 44 ( 17): 2608– 14.
    1. Health NIo, Institute NC (2009). Common Terminology Criteria for Adverse Events v4.0 (CTCAE). U.S.Department Of Health And Human Services; May 28, 2009. (v4.03: June 14, 2010).
    1. Bitran JD, Desser RK, Billings AA, Kozloff MF, Shapiro CM. (1982). Acute nephrotoxicity following cis-dichlorodiammine-platinum. Cancer, 49 ( 9): 1784–8.
    1. Markmann M, Rothman R, Reichman B, Hakes T, Lewis JL, Jr., Rubin S, Jones W, Almadrones L, Hoskins W. (1991). Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. J Cancer Res Clin Oncol, 117 ( 2): 89–90.
    1. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Leyssac PP, Amtorp O, Dikhoff TG. (1986). Acute effect of cisplatin on renal hemodynamics and tubular function in dog kidneys. Renal Physiol, 9 ( 5): 308–16.
    1. Coudray C, Rambeau M, Feillet-Coudry C, Gueux E, Tressol JC, Mazur A, Rayssiguier Y. (2005). Study of magnesium bioavailability from ten organic and inorganic Mg salts in Mg-depleted rats using a stable isotope approach. Magnesium Res, 18 ( 4): 215–23.
    1. Ariceta G, Rodriguez-Soriano J, Vallo A, Navajas A. (1997). Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediat Oncol, 28 ( 1): 35–40.
    1. Zekri J, Cheah NL, Evans L, Hancock B. (2009). Serum potassium, calcium and magnesium in patients receiving ESHAP chemotherapy for relapsed lymphomas. J R Coll Physicians Edinb, 39 ( 4): 301–6.
    1. Ohnuma T, Holland JF. (1977). Nutritional consequences of cancer chemotherapy and immunotherapy. Cancer Res, 37 ( 7 Pt 2): 2395–406.
    1. Lajer H, Kristensen M, Hansen HH, Christensen S, Jonassen T, Daugaard G. (2005). Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemother Pharmacol, 55 ( 3): 231–6.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren